Gilead Sciences

Executive Summary

Gilead Sciences is a leading biopharmaceutical company with a strong foundation in virology, particularly HIV and hepatitis, and a growing oncology franchise. The company's flagship HIV product, Biktarvy, continues to generate substantial revenue, while its cell therapy unit Kite (Yescarta and Tecartus) drives growth in oncology. Gilead's pipeline includes promising candidates in HIV prevention (lenacapavir), oncology (Trodelvy in multiple indications), and inflammation. With a robust balance sheet and consistent cash flow, Gilead is well-positioned to invest in R&D and business development. However, patent expirations on key drugs and increasing competition in HIV and oncology present challenges. Overall, Gilead's diversified portfolio and pipeline provide a stable outlook with select growth opportunities.

Upcoming Catalysts (preview)

• Q3 2026Lenacapavir for HIV PrEP: FDA decision or phase 3 data80% success
• Q3 2026Trodelvy phase 3 readout in metastatic non-small cell lung cancer60% success
• Q4 2026Kite CAR-T therapy update in autoimmune diseases50% success